Dark

QGEN
QIAGEN N.V.
stock NYSE

Market Open

Dec 4, 2025 11:37:32 AM EST

47.14USD+0.683%(+0.32)577,092

47.13Bid 47.15Ask 0.02Spread

Pre-market

Dec 4, 2025 9:21:30 AM EST

46.98USD+0.342%(+0.16)5,399

After-hours

Dec 3, 2025 4:23:30 PM EST

46.19USD-1.346%(-0.63)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 27, 2022

12:29PM EST QIAGEN's Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes Business Wire

Jan 25, 2022

01:30AM EST QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance Business Wire

Jan 19, 2022

08:20AM EST QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021 Business Wire

Jan 18, 2022

04:08PM EST QIAGEN Launches QIAwave Portfolio Of Environmentally Friendly Products Benzinga

Jan 14, 2022

02:32PM EST White House Official Says May Purchase More Than 1B At-Home Tests; Says 'We're Not Stopping There;' Orders Will Be Limited To 4 Tests Per Residential Address; Tests Will Ship Within 7-12 Days Of Ordering Benzinga

Jan 13, 2022

11:49AM EST What Does Qiagen's Debt Look Like? Benzinga

11:49AM EST QIAGEN Says Co's Liquid-Based Sample-Prep-And-Detection Kit Helps Labs Ramp Up COVID Testing Benzinga

Jan 11, 2022

10:44AM EST 'FDA Acting Commissioner Woodcock on rapid tests. There are now total of 15 authorized by FDA. New program in place to accelerate review of these tests.' -News Nation Reporter Benzinga

Jan 10, 2022

03:44PM EST US Health & Human Services Says, Starting Jan. 15, 2022, Individuals With Private Health Insurance/Group Health Plan Who Buy Over-The-Counter COVID Tests Will Have Costs Covered By Plan/Insurance Benzinga

02:28PM EST White House Says Expects To Have All Contracts For New Rapid Test Awarded Over Next 2 Weeks Benzinga

10:13AM EST QIAGEN Says Expands QIAstat-Dx Syndromic Testing Menu, Announces Launch Plans For QIAstat-Dx Rise Higher-Throughput Version Benzinga

10:12AM EST QIAGEN expands QIAstat-Dx syndromic testing menu and announces launch plans for new QIAstat-Dx Rise higher-throughput version Business Wire

Jan 7, 2022

01:01PM EST QIAGEN Announced New Collaborations to Extend the QIAcuity Ecosystem Benzinga

01:48AM EST QIAGEN Enters Collaborations That Extend QIAcuity RTTNews

01:34AM EST QIAGEN Enters Into Two New Collaborations That Extend QIAcuity ecosystem RTTNews

01:30AM EST QIAGEN Strengthens Growing Portfolio of Applications for Its Digital PCR Platform QIAcuity With New Collaborations Business Wire

Jan 6, 2022

04:05PM EST QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB Business Wire

Dec 28, 2021

10:27AM EST New York City To Double In-School PCR COVID Testing When Students Return Benzinga

Dec 23, 2021

12:19PM EST White House Still Working To Finalize Contracts For US Orders Of COVID Tests; COVID Testing Stocks Quiet Benzinga

Dec 22, 2021

02:35PM EST FDA Website Shows Dec. 22-Dated update On Antigen Tests For Omicron: 'The FDA continues to monitor and evaluate the impact of genetic variants on antigen tests...' Benzinga

Dec 21, 2021

04:39PM EST President Biden Tweets 'Starting this week, the federal government will set up emergency testing sites in areas that need additional testing capacity. Before Christmas, the first several of these federal testing sites will be up and running in New York..' Benzinga

12:18PM EST Fauci Says President Biden To Leverage Defense Production Act To Spur 200M To 500M COVID Tests To Market Benzinga

12:17PM EST New York Attorney General Issues Post 'Attorney General James Issues Warning to LabQ Diagnostics to Stop Misrepresenting Turnaround Times for COVID-19 Test Results' Benzinga

Dec 17, 2021

11:17AM EST COVID Testing Plays Quiet Following Headline Biden Admin. Will Push For 'Test-To-Stay' Policy To Keep Kids In School Benzinga

Dec 14, 2021

11:05AM EST UPDATE: M&A Blog Betaville Says BioMerieux Rumored To Be Moving Closer To Striking A Deal To Merger With Qiagen Benzinga

08:25AM EST Wells Fargo Maintains Equal-Weight on Qiagen, Raises Price Target to $60 Benzinga

Dec 9, 2021

09:48PM EST Denovo Biopharma And QIAGEN Partner To Develop Companion Diagnostic Test For The Treatment Of Diffuse Large B-Cell Lymphoma Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

09:42PM EST 'Senate votes to repeal key Biden administration vaccine and testing policy' -Earlier Washington Post Report Benzinga

09:31AM EST Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for PR Newswire

01:46AM EST Qiagen (QGEN) and Denovo Biopharma said that they have collaborated to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo's investigational cancer drug DB102 for treatment of diffuse large B-cell lymphoma or DLBCL, one of the most common lymphoid cancers. RTTNews

01:34AM EST QIAGEN, Denovo Biopharma To Develop Companion Diagnostic Test For Treatment Of Diffuse Large B-Cell Lymphoma RTTNews

01:30AM EST QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Business Wire

Dec 2, 2021

09:29AM EST White House Chief Of Staff Ronald Klain Says President Biden Will Announce Today 'FREE and RELIABLE' COVID At Home Tests Benzinga

01:25AM EST Qiagen N.V. (QGEN) said that it has launched the CE marked version of QuantiFERON SARS-CoV-2 to assess T-cell response to the COVID-19. The assay can detect T-cell response early in the course of COVID-19 infection or following vaccination. RTTNews

01:10AM EST QIAGEN Launches CE-marked Version of QuantiFERON(r) SARS-CoV-2 to Assess T-cell Response to COVID-19 Business Wire

Nov 30, 2021

06:24PM EST 'Stricter coronavirus testing to be required for all travelers to the U.S. amid omicron variant concerns' -Washington Post Report Benzinga

Nov 29, 2021

01:25AM EST QIAGEN (QGEN) and DiaSorin said Monday that the U.S. Food and Drug Administration has approved the LIAISON QuantiFERON-TB Gold Plus assay for use on DiaSorin's automated LIAISON XS platform. RTTNews

01:16AM EST QIAGEN : FDA Approves QuantiFERON-TB Gold Plus Assay On LIAISON XS Platform RTTNews

01:10AM EST QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON(r)-TB Gold Plus assay on LIAISON(r) XS Business Wire

Nov 26, 2021

01:05PM EST Qiagen N.V. (QGEN) Friday announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa. RTTNews

09:23AM EST QIAGEN Reaffirms Effectiveness Of SARS-CoV-2 PCR Tests In Light Of New Coronavirus Variant B.1.1.529 RTTNews

09:20AM EST QIAGEN Reaffirms Effectiveness Of Its SARS-CoV-2 PCR Tests In Light Of New Coronavirus Variant B.1.1.529 Benzinga

Nov 5, 2021

04:07PM EDT QIAGEN, Becton Dickinson Settle Patent Infringement Suit; BD Will Receive 1-Time, Lump Sum Payment Of $53M Benzinga

Nov 4, 2021

07:24AM EDT Qiagen Clocks 17% Increase In Non-COVID Product Sales; Raises FY21 Guidance Benzinga

Nov 3, 2021

06:51PM EDT Qiagen Q3 EPS $0.58 Beats $0.47 Estimate, Sales $535.00M Beat $434.97M Estimate Benzinga

05:55PM EDT Qiagen NV (QGEN) on Wednesday raised its outlook for full-year 2021 based on the stronger-than-expected third-quarter results. Net sales are now expected to grow at least 15 percent at constant exchange rates or CER and adjusted EPS is expected at $2.48 CER. Earlier, the company was expecting adjusted earnings per share to be at least $2.42 CER. RTTNews

05:34PM EDT Qiagen NV (QGEN) announced earnings for its third quarter that rose from the same period last year. RTTNews

05:33PM EDT Qiagen NV (QGEN) announced a profit for its third quarter that rose from the same period last year. RTTNews

05:19PM EDT Qiagen Q3 EPS $0.57 Vs. $0.07 Year Ago RTTNews

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Nov 2, 2021

04:27PM EDT QIAGEN Expands QIAstat-Dx Testing Menu With Respiratory 4-Plex Panel That Differentiates Between Flu, RSV And SARS-CoV-2 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 20, 2021

09:20AM EDT QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021 Business Wire

Oct 19, 2021

04:06PM EDT QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test For High-Burden Regions Benzinga

Oct 14, 2021

11:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 Benzinga

07:09AM EDT Redburn Partners Initiates Coverage On Qiagen with Buy Rating Benzinga

Oct 5, 2021

01:13PM EDT FDA Warns Of Potential For False Positive Results With Certain Lots Of Ellume COVID-19 Home Tests Due To Manufacturing Issue Benzinga

07:45AM EDT Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Companys Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. GlobeNewswire Inc

Oct 1, 2021

07:19AM EDT Qiagen Secures DoD Contract To Boost Production Capacity For NeuMoDx Benzinga

Sep 30, 2021

04:50PM EDT QIAGEN Receives $3.4M US Department Of Defense Contract To Further Expand Production Capacity For NeuMoDx Benzinga

Aug 27, 2021

10:20AM EDT Qiagen CFO Sacker Says We Believe In Our Own Growth Potential, Says He Does Not Rule Out Mergers Or Tie-Ups That Generate Value; Says Growing COVID-Business Is An Additional Upside To Our 2021 Guidance Benzinga

Aug 23, 2021

04:07PM EDT QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

04:58PM EDT QIAGEN And GT Molecular Collaborate To Offer A Complete SARS-CoV-2 Wastewater Detection Solution Based On QIAcuity Digital PCR Technology Benzinga

09:11AM EDT Qiagen Inks Companion Diagnostic Development, Technology-Licensing Deal With OncXerna Benzinga

Aug 9, 2021

05:15PM EDT QIAGEN Reports Licensing, Master Companion Diagnostics Deal With OncXerna, No Terms Disclosed Benzinga

Aug 6, 2021

04:20PM EDT Qiagen's COVID-19 Antigen Test Gets FDA Emergency Use Approval Benzinga

01:19PM EDT Qiagen Receives U.S. FDA Emergency Use Authorization For Rapid Portable Test That Can Analyze Over 30 Samples/Hour For SARS-Cov-2 Antigen Benzinga

Jul 29, 2021

05:14PM EDT Qiagen NV (QGEN) announced a profit for its second quarter that advanced from the same period last year. RTTNews

05:01PM EDT Qiagen Q2 EPS $0.52 Vs. $0.38 Year Ago RTTNews

04:15PM EDT Qiagen Q2 EPS $0.66 Beats $0.62 Estimate, Sales $567.30M Beat $554.42M Estimate; $100M Buyback Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 14, 2021

10:04AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021 Benzinga

05:47AM EDT Kepler Cheuvreux Downgrades Qiagen to Hold, Announces $49.53 Price Target Benzinga

Jul 12, 2021

09:47PM EDT Qiagen N.V. (QGEN) announced preliminary results for the second quarter of 2021 that exceeded its outlook. The company reduced its guidance for full-year 2021 based on the success of vaccination campaigns that has led to a reduction in COVID-19 testing trends. RTTNews

01:47PM EDT Qiagen Down 5% On Lowered Outlook RTTNews

12:53PM EDT Qiagen Stock Drops After Trimming FY21 Earnings Forecast On Weaker COVID-19 Testing Trends Benzinga

11:55AM EDT QIAGEN To Host Call July 13 To Discuss Preliminary Q2 2021 Results Reported Earlier Benzinga

11:55AM EDT QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results Business Wire

11:18AM EDT QIAGEN Sees H1 2021 Sales $1.135B Benzinga

11:17AM EDT QIAGEN Reports $100M Buyback Benzinga

11:17AM EDT GIAGEN Sees Q2 2021 Adj. EPS $0.66-$0.67 Vs $0.62 Est Benzinga

11:16AM EDT QIAGEN Sees Net Sales $567.3M Vs $554.42M Est Benzinga

11:05AM EDT Qiagen Shares Halted On Code News Pending Benzinga

Jul 8, 2021

04:23PM EDT QIAGEN Says Co's NeuMoDx HAdV Quant Assay Secures CE-IVD Certification For Automated Testing To Detect Human Adenovirus Infections Benzinga

Jul 1, 2021

05:06PM EDT Labcorp Launches Companion Diagnostic For Amgen's Newly-Approved Lung Cancer Therapy Benzinga

Jun 29, 2021

04:06PM EDT QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions Benzinga

Jun 22, 2021

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

06:45AM EDT Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments Benzinga

Jun 21, 2021

04:06PM EDT QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments Benzinga

Jun 3, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 Benzinga

May 28, 2021

02:29PM EDT Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer Benzinga

01:46PM EDT QIAGEN Highlights Launch Of Expanded Scope Of Companion Diagnostic Claims For Therascreen Kit Benzinga

May 26, 2021

07:33AM EDT The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing Benzinga

May 25, 2021

04:13PM EDT QIAGEN Reports Partnership With Mirati Therapeutics To Develop KRASG12C Companion Diagnostic For Non-Small Cell Lung Cancer Benzinga

May 17, 2021

06:49AM EDT QIAGEN N.V. (QGEN) announced Monday the creation of a Scientific Advisory Board as well as updates on the Supervisory Board ahead of the Annual General Meeting to be held virtually on June 29, 2021. RTTNews

06:27AM EDT QIAGEN Announces Creation Of A Scientific Advisory Board RTTNews

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

May 12, 2021

04:27PM EDT Qiagen N.V. (QGEN) Wednesday said that FDA has given Emergency Use Authorization to its Covid-19 test QIAreach Anti-SARS-CoV-2 Total Test. RTTNews

04:18PM EDT QIAGEN Receives FDA Emergency Use Authorization For QIAreach Digital Test To Detect SARS-CoV-2 Coronavirus Antibodies Benzinga

04:12PM EDT QIAGEN Receives Emergency Use Authorization From FDA For Fast And Easy-to-use QIAreach Anti-SARS-CoV-2 Total Test RTTNews

04:05PM EDT QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies Business Wire

May 4, 2021

07:10AM EDT Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues Benzinga

May 3, 2021

05:00PM EDT Recap: Qiagen Q1 Earnings Benzinga

04:36PM EDT Qiagen NV (QGEN) revealed earnings for its first quarter that climbed from the same period last year. RTTNews

04:31PM EDT UPDATE: Qiagen Q1 Adj. EPS $0.65 On Constant Exchange Rate Basis Benzinga

04:31PM EDT Qiagen Q1 Adj. EPS $0.65 On Constant Exchange Rate Basis Beats $0.63 Estimate, Sales $567.20M Beat $557.50M Estimate Benzinga

04:30PM EDT Qiagen Q1 Adj. EPS $0.66 Beats $0.63 Estimate, Sales $567.20M Beat $557.50M Estimate Benzinga

04:16PM EDT QIAGEN Q1 Adj. EPS Up 94% To $0.66 RTTNews

04:13AM EDT Earnings Scheduled For May 3, 2021 Benzinga

Apr 30, 2021

10:41AM EDT Qiagen's Earnings: A Preview Benzinga

Apr 29, 2021

04:43PM EDT QIAGEN Reports EZ2 Connect Instrument Line For Automated Sample Processing In Research, Forensics, Diagnostics Benzinga

Apr 21, 2021

05:37AM EDT QIAGEN Announced Launch of New LIAISON LymeDetect Assay Based on QuantiFERON Technology in Countries Accepting CE Mark for Early Diagnosis of Lyme Borreliosis Benzinga

01:03AM EDT QIAGEN Announces Launch Of LIAISON LymeDetect Assay For Markets accepting The CE Mark RTTNews

01:00AM EDT QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON(r) LymeDetect(r) Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis Business Wire

Apr 20, 2021

04:08PM EDT QIAGEN Launches artus Prep&Amp Kit Benzinga

04:05PM EDT QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity Business Wire

05:55AM EDT QIAGEN N.V. to Report First Quarter 2021 Results Business Wire

Apr 12, 2021

07:50AM EDT What Does Qiagen's Debt Look Like? Benzinga

Apr 7, 2021

07:58AM EDT The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award Benzinga

Apr 6, 2021

04:06PM EDT QIAGEN Highlights Launch Of QIAseq DIRECT SARS-CoV-2 Kit 'a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols' Benzinga

04:05PM EDT QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance Business Wire

Mar 29, 2021

03:14AM EDT Qiagen N.V. (QGEN) announced Monday that the U.S. Food and Drug Administration or FDA has granted Emergency Use Authorization for the NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test. RTTNews

02:05AM EDT QIAGEN Secures FDA Emergency Use Authorization For NeuMoDx Multiplex Test Expanding COVID-19 Portfolio RTTNews

02:00AM EDT QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio Business Wire

Mar 3, 2021

04:12PM EST QIAGEN Highlights Launch Of QIAsphere Cloud-Based Connectivity Solution To Enhance QIAstat-Dx Capabilities In Digital Diagnostics Benzinga

Mar 2, 2021

04:12PM EST QIAGEN Highlights Launch Of QIAcube Connect MDx Platform For Automated Sample Processing In Diagnostic Labs Benzinga

Feb 24, 2021

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

07:26AM EST Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics Benzinga

02:20AM EST Inovio Pharmaceuticals Inc. (INO) and Qiagen N.V. (QGEN) announced Wednesday their collaboration to develop next generation sequencing or NGS companion diagnostic for Inovio's VGX-3100 for advanced cervical dysplasia. RTTNews

01:51AM EST INOVIO, QIAGEN Collaborate To Develop Next Generation Sequencing Companion Diagnostic For INOVIO's VGX-3100 RTTNews

01:45AM EST (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia PR Newswire

Feb 22, 2021

04:20PM EST QIAGEN Appoints Thomas Ebeling As A Member Of Supervisory Board RTTNews

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 9, 2021

11:03PM EST Qiagen N.V. (QGEN) reported that its fourth-quarter net income surged to $212.69 million or $0.91 per share from $44.93 million or $0.19 per share in the prior year. RTTNews

05:48PM EST Recap: Qiagen Q4 Earnings Benzinga

04:35PM EST Notable After-Hours Earnings For Tuesday, Feb. 9, 2021 And Expected Report Times: AKAM, TWTR, CSCO, LYFT, QGEN, ENPH, MAT, YELP, CCK, AI Benzinga

04:14PM EST Qiagen Q4 EPS $0.68 Beats $0.65 Estimate, Sales $571.20M Beat $548.86M Estimate Benzinga

04:11PM EST QIAGEN Q4 Adjusted EPS Up 42% To $0.68 RTTNews

03:44PM EST Notable After-Hours Earnings For Tuesday, Feb. 9, 2021 And Expected Report Times: AKAM, TWTR, CSCO, LYFT, QGEN, FSRV, ENPH, MAT, YELP, CCK, AI Benzinga

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

04:05AM EST Earnings Scheduled For February 9, 2021 Benzinga

Feb 8, 2021

10:19AM EST A Preview Of Qiagen's Earnings Benzinga

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

Jan 26, 2021

07:10AM EST QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results Business Wire

Jan 20, 2021

04:08PM EST QIAGEN Reports Plan To Resubmit Emergency Use Authorization Submission In US For QIAreach SARS-CoV-2 Antigen Test In Q1'21 Benzinga

04:05PM EST QIAGEN Confirms Effectiveness Of SARS-CoV-2 PCR Tests Amid Mutations Benzinga

Jan 19, 2021

10:03AM EST GNS Healthcare To Enter Partnership With Qiagen; Parties Will Leverage Gemini In Silico Patient Across Multiple Cancers Benzinga

Jan 8, 2021

07:42AM EST QIAGEN Names Toralf Haag Member Of The Supervisory Board RTTNews

Dec 10, 2020

10:01AM EST Shares of QIAGEN N.V. (QGEN) are currently trading at $51.28, up $1.80 or 3.64% Thursday morning, with trading volume of 337K versus an average volume of 860K shares. The stock has been trading in the range of $30.23 - $55.27 for the past one year. RTTNews

01:56AM EST QIAGEN Launches Non-U.S. Offering Of Net Share Settled Convertible Bonds RTTNews

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

06:27AM EST QIAGEN Earlier ISsued Guidance Sees Q4 Adj. EPS $0.64-$0.65 vs $0.62 Est., FY21 Adj. EPS $2.42-$2.46 vs $2.40 Est. Benzinga

02:46AM EST Qiagen N.V. (QGEN) said it raised its fourth-quarter and full-year 2020 outlook. It expects another strong performance in 2021. The company will expand its supervisory board. RTTNews

02:02AM EST QIAGEN Raises Full-year 2020 Outlook For Growth Of Net Sales And Adjusted EPS RTTNews

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

04:06PM EST QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck Benzinga

Nov 17, 2020

08:03AM EST Leading Diagnostics Companies Join Forces to Establish the Access to PR Newswire

Nov 16, 2020

04:07PM EST QIAGEN Launches NeuMoDx Multiplex Test In Europe To Identify And Differentiate Between Patients With Common Seasonal Respiratory Infections And COVID-19 Benzinga

Nov 12, 2020

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

04:07PM EST QIAGEN Highlights Launch Of Portable Digital SARS-CoV-2 Antigen Test Can Accurately Analyze 30+ Samples/Hr Benzinga

Oct 27, 2020

09:58PM EDT Qiagen N.V. (QGEN) reported that its third-quarter net income was $16.91 million or $0.07 per share compared to a loss of $160.64 million or $0.71 per share in the previous year. RTTNews

01:04PM EDT QIAGEN N.V. to hold investor call on Wednesday, October 28, after releasing results for Q3 2020 and first nine months of 2020 Business Wire

01:01PM EDT UPDATE: QIAGEN Raises FY20 Guidance: Adj. EPS To $2.07-$2.09 vs $2.06 Estimate, Sales Growth ~20% Benzinga

01:01PM EDT Qiagen Q3 EPS $0.58 Up From $0.36 YoY, Sales $483.80M Up From $382.70M YoY Benzinga

12:53PM EDT Qiagen Sees Q4 Net Sales About +24% To +27%; Sees FY Net Sales About +20%, Saw About +15% To +18%l Sees FY Adj. EPS About $2.07 To $2.09; Est. $2.05 Benzinga

12:52PM EDT QIAGEN Raises FY20 Net Sales Growth Guidance From 15-18% To 20+% Benzinga

Oct 13, 2020

09:11AM EDT Qiagen N.V. (QGEN) reported that preliminary adjusted earnings per share for the third quarter of 2020 were about $0.58 at constant exchange rates, a 61% increase from adjusted earnings per share of $0.36 in the third quarter of 2019 and at the high end of the outlook for about $0.52-$0.58 at CER. RTTNews

08:53AM EDT QIAGEN Sees Q3 Adj. EPS ~$0.58, Above The $0.52-$0.58 Guidance Issued Jul. 13, 2020, vs $0.56 Consensus Estiamte, Net Sales Up 26% To $481.3M, Above The Previously-Issued 16-21% Guidance, vs $461M Est. Benzinga

08:48AM EDT QIAGEN Sees Q3 Adj. EPS ~$0.58, Above The $0.52-0.58 Guidance Issued Jul. 13, 2020, Net Sales Up 26% To $481.3M, Above The Previously-Issued 16-21% Guidance Benzinga

08:48AM EDT QIAGEN Q3 Net Sales Up 26% At Actual Rates, Up 26% At Constant Exchange Rates To $481.3 Mln RTTNews

08:45AM EDT QIAGEN reports strong preliminary results for third quarter of 2020 Business Wire

Oct 6, 2020

01:01PM EDT BofA Likes Qiagen After Thermo Fisher Deal Fails To Get Shareholder Approval Benzinga

07:22AM EDT B of A Securities Upgrades Qiagen to Buy, Announces $59 Price Target Benzinga

Oct 5, 2020

04:05PM EDT QIAGEN Announces Novel Coronavirus Test Kit That 'Simplifies And Accelerates PCR Analysis For Research Applications' Benzinga

04:03PM EDT QIAGEN to Complement COVID-19 Testing Portfolio With Novel Kit That Simplifies and Accelerates PCR Analysis for Research Applications Business Wire

Sep 28, 2020

12:42PM EDT Qiagen NV shares are trading higher after Kepler Cheuvreux upgraded the stock from Hold to Buy and announced a price target of $59.32 per share. Benzinga

09:31AM EDT Benzinga's Top Upgrades, Downgrades For September 28, 2020 Benzinga

06:33AM EDT Kepler Cheuvreux Upgrades Qiagen to Buy, Announces $59.32 Price Target Benzinga

Sep 17, 2020

04:07PM EDT QIAGEN Fully Acquires NeuMoDx Molecular RTTNews

04:06PM EDT QIAGEN Reports Purchase Of REmaining 80.1% Stake In NeuMoDx Molecular For $248M Benzinga

04:05PM EDT QIAGEN fully acquires NeuMoDx Molecular, Inc., rounding out portfolio of PCR-based diagnostic automation systems Business Wire

07:18AM EDT Bio-Techne Corp. (TECH) and Netherlands-based Qiagen NV (QGENF) announced Thursday the expansion and extension of a non-exclusive partnership to co-market exosome technology to existing and potential biopharma partners as well as the joint development of new exosome based products. RTTNews

07:07AM EDT Bio-Techne And QIAGEN Announce Expansion And Extension Of Exosome Partnership Benzinga

07:03AM EDT Bio-Techne And QIAGEN Announce Expansion And Extension Of Non-exclusive Partnership RTTNews

Sep 8, 2020

04:07PM EDT QIAGEN To Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour For SARS-CoV-2 Antigen RTTNews

04:02PM EDT QIAGEN Reports Will Launch Rapid Portable Test That Can Analyze 30+ Samples/Hour For Coronavirus Antigen Benzinga

04:02PM EDT QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen Business Wire

Aug 26, 2020

09:42AM EDT Benzinga's Top Upgrades, Downgrades For August 26, 2020 Benzinga

06:46AM EDT Commerzbank Upgrades Qiagen to Buy, Announces $66 Price Target Benzinga

Aug 24, 2020

04:02PM EDT QIAGEN to Launch Easy-to-Use Digital Test in the U.S. for Rapid Detection of SARS-CoV-2 Antibodies Following FDA Emergency Use Authorization Benzinga

09:34AM EDT Benzinga's Top Upgrades, Downgrades For August 24, 2020 Benzinga

06:13AM EDT Citigroup Upgrades Qiagen to Buy, Raises Price Target to $62 Benzinga

Aug 21, 2020

09:15PM EDT Netherlands-based Qiagen N.V. (QGEN) said that Hkan Bjrklund has resigned as Chairman of the Supervisory Board with immediate effect and has left the Supervisory Board. RTTNews

11:52AM EDT QIAGEN announces new Chairman of Supervisory Board Business Wire

Aug 20, 2020

10:01AM EDT JP Morgan Reinstates Overweight on Qiagen, Announces $60 Price Target Benzinga

Aug 14, 2020

11:48AM EDT Why Qiagen's Stock Is Trading Higher Today Benzinga

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 14, 2020 Benzinga

08:43AM EDT Exane BNP Paribas Upgrades Qiagen to Outperform Benzinga

08:21AM EDT Deutsche Bank Upgrades Qiagen to Buy, Raises Price Target to $60 Benzinga

07:34AM EDT 07:34 Friday, August 14, 2020William Blair (RTTNews) - William Blair Reiterates Qiagen NV (QGEN) At Market Perform RTTNews

07:33AM EDT 07:32 Friday, August 14, 2020Wedbush (RTTNews) - Wedbush Reiterates Qiagen NV (QGEN) At Market Perform RTTNews

Aug 13, 2020

08:34AM EDT QIAGEN Says Will 'Continue Successful Growth Strategy Focused on Execution and Greater Value Creation' After Thermo Fisher Takeover Failed To Achieve 66.67% Acceptance; Says Will Move Forward With NeuMoDx Acquisition Benzinga

08:00AM EDT Davidson Kempner On Qiagen Says We Look To Refocus Strategy Towards A High Growth Business With A Disciplined Capital Allocation Framework Benzinga

07:42AM EDT Thermo Fisher Scientific Inc. (TMO) said the company's offer to acquire all of the ordinary shares of QIAGEN N.V. (QGEN) has lapsed as the minimum acceptance threshold condition to the offer has not been satisfied. Thermo Fisher has terminated the acquisition deal with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of $95 million in cash. RTTNews

07:38AM EDT Thermo Fisher Scientific And QIAGEN Announce Lapse Of Offer And Termination Of Acquisition Agreement; QIAGEN To Pay Thermo Fisher $95M Reimbursement Payment In Accordance With The Terms Of The Acquisition Agreement Benzinga

07:35AM EDT Thermo Fisher Scientific Says Offer To Acquire QIAGEN Has Lapsed; Minimum Acceptance Threshold Not Satisfied RTTNews

07:31AM EDT Thermo Fisher Scientific Announces Results of Offer to Acquire QIAGEN, Lapse of PR Newswire

Aug 11, 2020

09:28AM EDT Thermo Fisher To Publicly Announce Final Results Of Acceptance Period Of Its Offer For QIAGEN RTTNews

09:24AM EDT Thermo Fisher Scientific Provides Process Overview for the Announcement of PR Newswire

Aug 10, 2020

04:16PM EDT HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN Benzinga

04:01PM EDT HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (QIAGEN). GlobeNewswire Inc

Aug 6, 2020

11:51AM EDT Hedge Fund Davidson Kempner Says It Will Not Be Tendering Qiagen Shares Into 'The Current Offer' Benzinga

Aug 4, 2020

06:05PM EDT QIAGEN N.V. (QGEN) reported that its second quarter adjusted earnings per share increased to $0.55 ($0.56 CER), from $0.33, last year. On average, ten analysts polled by Thomson Reuters expected the company to report profit per share of $0.46, for the quarter. Analysts' estimates typically exclude special items. RTTNews

05:34PM EDT Qiagen: Q2 Earnings Insights Benzinga

05:18PM EDT Qiagen Q2 EPS $0.38 Vs. $0.19 Year Ago RTTNews

04:54PM EDT QIAGEN Says Boards 'have reaffirmed unanimous recommendation that QIAGEN shareholders accept Thermo Fisher Offer and tender their shares on or before August 10' Benzinga

04:44PM EDT Qiagen Q2 Adj. EPS $0.55 Beats $0.46 Estimate, Sales $443.30M Beat $425.82M Estimate Benzinga

04:14PM EDT Thermo Fisher Scientific Confirms That QIAGEN Offer Expires On August 10 RTTNews

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Aug 3, 2020

04:30PM EDT Qiagen 13D Filing From Davidson Kempner Confirms Earlier Report Of Stake; Filing Shows 7.98% Stake In Co. Benzinga

10:31AM EDT UPDATE: Davidson Kempner Sees Qiagen's Current Takeover Offer Failing, Sees Current Price As Very Attractive Entry Point Benzinga

10:31AM EDT Qiagen Shareholder Davidson Kempner Says Now Holds 8% Stake In Co., Sees Co.'s Standalone Prospects As 'Highly Attractice' Benzinga

Jul 24, 2020

10:32AM EDT Stocks That Hit 52-Week Highs On Friday Benzinga

Jul 16, 2020

09:07AM EDT U.S. laboratory equipment maker Thermo Fisher Scientific Inc. (TMO) and Netherlands-based Qiagen N.V. (QGEN) announced Thursday that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of Qiagen. RTTNews

08:53AM EDT Thermo Fisher Scientific, QIAGEN Amend Terms To Acquisition Agreement; Offer Price Increase To EUR 43.00/Shr RTTNews

08:45AM EDT Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition PR Newswire

08:41AM EDT QIAGEN Reports Thermo Fisher Wholly-Owned Subsidiary, Quebec B.V., Will Raise Cash Offer For QIAGEN From 39 To 43/Share Benzinga

Jul 15, 2020

11:27AM EDT Davidson Kempner Sends Letter To Qiagen Board Benzinga

Jul 13, 2020

09:40AM EDT QIAGEN Updates Prelim. Q2 Results; Issues Outlook - Quick RTTNews

09:06AM EDT QIAGEN Expects Q3 Net Sales Growth Of 16-21% At CER, Adj. EPS To Grow 45-60% CER RTTNews

09:01AM EDT Qiagen Announces Its Outlook For Q3 And Full-Year 2020 For Net Sales And Adjusted Earnings Per Share As Well As Expectations For 2021 Benzinga

document.getElementById("Ptf8zV").onerror = function(){this.style.display='none';}; .dark-mode .QHk0qG{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .QHk0qG{ color: #333333; background-color: white; border: 2px solid #333333; }QGENQIAGEN N.V.stock NYSE

QGEN
QIAGEN N.V.
stock NYSE